Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells

Cancer Research

Volumn 75, Issue 21, 2015, Pages 4517-4526

  Vences Catalán, Felipe ^a   Rajapaksa, Ranjani ^a   Srivastava, Minu K ^a   Marabelle, Aurelien ^b   Kuo, Chiung Chi ^a   Levy, Ronald ^a   Levy, Shoshana ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CD81 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE DEFICIENCY; IMMUNOMODULATION; INNATE IMMUNITY; KNOCKOUT MOUSE; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ESCAPE; TUMOR GROWTH; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; C57BL MOUSE; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD81; CELL LINE, TUMOR; CELL PROLIFERATION; IMMUNITY, INNATE; IMMUNOMODULATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; NEOPLASM METASTASIS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84946558893     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1021     Document Type: Article

References (57)

1. Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 2005;5:136-48.
2. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005;6:801-11.
3. Bassani S, Cingolani LA. Tetraspanins: Interactions and interplay with integrins. Int J Biochem Cell Biol 2012;44:703-8.
4. Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer 2014;14:49-60.
5. Zoller M. Tetraspanins: Push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009;9:40-55.
6. Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med 1993;178:1407-17.
7. Imai T, Kakizaki M, Nishimura M, Yoshie O. Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82. J Immunol 1995;155: 1229-39.
8. Atkinson B, Ernst CS, Ghrist BF, Herlyn M, Blaszczyk M, Ross AH, et al. Identification of melanoma-associated antigens using fixed tissue screening of antibodies. Cancer Res 1984;44:2577-81.
9. Azorsa DO, Hyman JA, Hildreth JE. CD63/Pltgp40: A platelet activation antigen identical to the stage-specific, melanoma-associated antigen ME491. Blood 1991;78:280-4.
10. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268:884-6.
11. Tang Y, Cheng Y, Martinka M, Ong CJ, Li G. Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. Carcinogenesis 2014;35:86-95.
12. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with nonsmall cell lung cancer. Cancer Res 1996;56:1751-5.
13. Testa JE, Brooks PC, Lin JM, Quigley JP. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 1999;59:3812-20.
14. Szala S, Kasai Y, Steplewski Z, Rodeck U, Koprowski H, Linnenbach AJ. Molecular cloning of cDNA for the human tumor-associated antigen CO- 029 and identification of related transmembrane antigens. Proc Natl Acad Sci U S A 1990;87:6833-7.
15. Matsumoto N, Morine Y, Utsunomiya T, Imura S, Ikemoto T, Arakawa Y, et al. Role of CD151 expression in gallbladder carcinoma. Surgery 2014;156:1212-7.
16. Copeland BT, Bowman MJ, Ashman LK. Genetic ablation of the tetraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model. Mol Cancer Res 2013;11:95-105.
17. Roselli S, Kahl RG, Copeland BT, Naylor MJ, Weidenhofer J, Muller WJ, et al. Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model. BMC Cancer 2014;14:509.
18. Li Q, Yang XH, Xu F, Sharma C, Wang HX, Knoblich K, et al. Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. Oncogene 2013; 32:1772-83.
19. Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley SJ, et al. Diminishedmetastasis in tetraspanin CD151-knockout mice. Blood 2011; 118:464-72.
20. Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 1990;10:4007-15.
21. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41.
22. Silvie O, Rubinstein E, Franetich JF, Prenant M, Belnoue E, Renia L, et al. Hepatocyte CD81 is required for Plasmodiumfalciparum and Plasmodium yoelii sporozoite infectivity. Nat Med 2003;9:93-6.
23. Rubinstein E, Ziyyat A, Prenant M, Wrobel E, Wolf JP, Levy S, et al. Reduced fertility of female mice lacking CD81. Dev Biol 2006;290:351-8.
24. Geisert EE Jr., Williams RW, Geisert GR, Fan L, Asbury AM, Maecker HT, et al. Increased brain size and glial cell number in CD81-nullmice. J Comp Neurol 2002;453:22-32.
25. Feneant L, Levy S, Cocquerel L. CD81 and hepatitis C virus (HCV) infection. Viruses 2014;6:535-72.
26. Levy S. Function of the tetraspanin molecule CD81 in B and T cells. Immunol Res 2014;58:179-85.
27. Hong IK, Byun HJ, Lee J, Jin YJ, Wang SJ, Jeoung DI, et al. The tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the pro-oncogenic Aktdependent Sp1 activation signaling pathways. J Biol Chem 2014;289: 15691-704.
28. Aslakson CJ, Miller FR. Selective events in themetastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992;52:1399-405.
29. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-67.
30. Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, Woo SL. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 2007;15:2194-202.
31. Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother 2014; 63:11-20.
32. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
33. Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S. Tumor-induced myeloid- derived suppressor cell function is independent of IFN-gamma and IL- 4Ralpha. Eur J Immunol 2012;42:2052-9.
34. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99-108.
35. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by maturemyeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49.
36. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010;70:68-77.
37. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloidderived suppressor cells. J Immunol 2009;182:5693-701.
38. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-83.
39. Miyazaki T, Muller U, Campbell KS. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J 1997;16:4217-25.
40. Maecker HT, Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med 1997;185:1505-10.
41. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 2009;69:5996-6004.
42. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010;33:225-35.
43. Deng L, Liang H, Burnette B, Weicheslbaum RR, Fu YX. Radiation and anti- PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology 2014;3:e28499.
44. DuPre SA, Redelman D, Hunter KW Jr. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 2007;88:351-60.
45. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006;176:284-90.
46. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1CD115 immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123-31.
47. Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012;7:e40677.
48. Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 2014;20:676-81.
49. Leung J, Suh WK. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. J Immunol 2013;190:6651-61.
50. Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloidderived suppressor cells in the tumor microenvironment. J Immunol 2012;189:5533-40.
51. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9.
52. Yan Z, Garg SK, Banerjee R. Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. J Biol Chem 2010;285:41525-32.
53. Psaila B, Lyden D. The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 2009;9:285-93.
54. Zhang HG, Grizzle WE. Exosomes: A novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 2014;184:28-41.
55. Andreu Z, Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. Front Immunol 2014;5:442. doi:10.3389/fimmu.2014.00442.
56. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012;151:1542-56.
57. Hazawa M, Tomiyama K, Saotome-Nakamura A, Obara C, Yasuda T, Gotoh T, et al. Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation. Biochem Biophys Res Commun 2014;446: 1165-71.